Invention Grant
- Patent Title: Methods for treatment using anti-alpha4beta7 antibody
-
Application No.: US16743813Application Date: 2020-01-15
-
Publication No.: US12053526B2Publication Date: 2024-08-06
- Inventor: Catherine Scholz , Irving H. Fox
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Womble Bond Dickinson (US) LLP
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K9/00 ; A61K9/19 ; A61K39/00 ; A61K47/18 ; A61K47/26 ; C07K16/28

Abstract:
Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
Public/Granted literature
- US20210052733A1 FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY Public/Granted day:2021-02-25
Information query